Factor V Leiden G1691A, Prothrombin G20210A, and MTHFR C677T and A1298C Mutations in Patients With Sickle Cell Disease in Tunisia

References

• Pauling L, Itano HA, Singer SJ, Wells IG. Sickle cell anemia, a molecular disease. Science. 1949;110(2865):543–548.
   PubMed Web of Science ®Google Scholar
• Masom VR. Sickle cell anemia. J Am Med Assoc. 1922;79(16):1318–1320.
   Google Scholar
• Bauer J. Sickle cell disease; pathogenetic, clinical and therapeutic considerations. Arch Surg. 1940;41:1344–1362.
   Google Scholar
• Fattoum S. Evolution of hemoglobinopathy prevention in Africa: results, problems and prospect. Mediterr J Hematol Infect Dis. 2009;1(1):e2009005.
   PubMedGoogle Scholar
• Eaton WA, Hofrichter J. Sickle cell hemoglobin polymerization. Adv Protein Chem. 1990;40:63–279.
   PubMedGoogle Scholar
• Rahimi Z, Parsian A. Sickle cell disease and venous thromboembolism. Mediterr J Hematol Infect Dis. 2011;3:e2011024.
   PubMedGoogle Scholar
• Steinberg MH. Management of sickle cell disease. N Engl J Med. 1999;340(13):1021–1030.
   PubMed Web of Science ®Google Scholar
• Solovey AA, Solovey AN, Harkness J, Hebbel RP. Modulation of endothelial cell activation in sickle cell disease: a pilot study. Blood. 2001;97(7):1937–1941.
   PubMed Web of Science ®Google Scholar
• Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev. 2007;21(1):37–47.
   PubMed Web of Science ®Google Scholar
• Nsiri B, Gritli N, Bayoudh F, et al. Abnormalities of coagulation and fibrinolysis in homozygous sickle cell disease. Hematol Cell Ther. 1996;38(3):279–284.
   PubMedGoogle Scholar
• Ohene-Frempong K, Steinberg MH. Clinical aspects of sickle cell anemia in adults and children. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL, Eds. Disorders of Hemoglobin Genetics, Pathophysiology, and Clinical Management. Cambridge (Cambridgeshire, UK): Cambridge University Press. 2001:611–670.
   Google Scholar
• Ataga KI, Cappellini MD, Rachmilewitz EA. β-Thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. Br J Haematol. 2007;139(1):3–13.
   PubMed Web of Science ®Google Scholar
• Francis RB. Large-vessel occlusion in sickle cell disease: pathogenesis, clinical consequences, and therapeutic implications. Med Hypotheses. 1991;35(2):88–95.
   PubMed Web of Science ®Google Scholar
• Stein PD, Beemath A, Meyers FA, et al. Deep venous thrombosis and pulmonary embolism in hospitalized patients with sickle cell disease. Am J Med. 2006;119(10):897–811.
   PubMed Web of Science ®Google Scholar
• Haque AK, Gokhale S, Rampy BA, et al. Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases. Hum Pathol. 2002;33(10):1037–1043.
   PubMed Web of Science ®Google Scholar
• Maggio A, Giambona A, Cai SP, et al. Rapid and simultaneous typing of Hemoglobin S, Hemoglobin C and seven Mediterranean β-thalassemia mutations by covalent reverse dot blot analysis: application to prenatal diagnosis in Sicily. Blood. 1993;81(1):239–242.
   PubMed Web of Science ®Google Scholar
• Old JM, Khan SN, Verma I, et al. A multi-center study in order to further define the molecular basis of β-thalassemia in Thailand, Pakistan, Sri Lanka, Mauritius, Syria, and India, and to develop a simple molecular diagnostic strategy by amplification refractory mutation system-polymerase chain reaction. Hemoglobin. 2001;25(4):397–407.
   PubMed Web of Science ®Google Scholar
• Akinsheye I, Alsultan A, Solovieff N, et al. Fetal hemoglobin in sickle cell anemia. Blood. 2011;118(1):19–27.
   PubMed Web of Science ®Google Scholar
• Serjeant GR. The natural history of sickle cell disease. Cold Spring Harb Perspect Med. 2013;3(10):a011783.
   PubMed Web of Science ®Google Scholar
• Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332(20):1317–1322.
   PubMed Web of Science ®Google Scholar
• Green D, Scott JP. Is sickle cell crisis a thrombotic event? Am J Hematol. 1986;23(4):317–321.
   PubMed Web of Science ®Google Scholar
• Francis RB Jr. Elevated fibrin D-dimer fragment in sickle cell anemia: evidence for activation of coagulation during the steady state as well as in painful crisis. Haemostasis. 1989;19(2):105–111.
   PubMedGoogle Scholar
• Westerman MP, Green D, Gilman-Sachs A, et al. Antiphospholipid antibodies, proteins C and S, and coagulation changes in sickle cell disease. J Lab Clin Med. 1999;134(4):352–362.
   PubMed Web of Science ®Google Scholar
• Tam DA. Protein C and protein S activity in sickle cell disease and stroke. J Child Neurol. 1997;12(1):19–21.
   PubMed Web of Science ®Google Scholar
• El-Hazmi MA, Warsy AS, Bahakim H. Blood proteins C and S in sickle cell disease. Acta Haematol. 1993;90(3):114–119.
   PubMed Web of Science ®Google Scholar
• Karayalcin G, Lanzkowsky P. Plasma protein C levels in children with sickle cell disease. Am J Pediatr Hematol Oncol. 1989;11(3):320–323.
   PubMedGoogle Scholar
• Liesner R, Mackie I, Cookson J, et al. Prothrombotic changes in children with sickle cell disease: relationships to cerebrovascular disease and transfusion. Br J Haematol. 1998;103(7):1037–1044.
   Web of Science ®Google Scholar
• Wright JG, Malia R, Cooper P, et al. Protein C and protein S in homozygous sickle cell disease: does hepatic dysfunction contribute to low levels? Br J Haematol. 1997;98(3)627–631.
   PubMed Web of Science ®Google Scholar
• Bayazit AK, Kilinç Y. Natural coagulation inhibitors (protein C, protein S, antithrombin) in patients with sickle cell anemia in a steady state. Pediatr Int. 2001;43(6):592–596.
   PubMed Web of Science ®Google Scholar
• Onyemelukwe GC, Bibril HB. Anti-thrombin III deficiency in Nigerian children with sickle cell disease. Possible role in the cerebral syndrome. Trop Geogr Med. 1992;44(1-2):37–41.
   PubMedGoogle Scholar
• Zimmerman SA, Ware RE. Inherited DNA mutations contributing to thrombotic complications in patients with sickle cell disease. Am J Hematol. 1998;59(4):267–272.
   PubMed Web of Science ®Google Scholar
• Wright JG, Cooper P, Malia RG, et al. Activated protein C resistance in homozygous sickle cell anaemia. Br J Haematol. 1997;96(4):854–856.
   PubMed Web of Science ®Google Scholar
• Andrade FL, Annichino-Bizzacchi JM, Saad STO, et al. Prothrombin mutant, factor V Leiden, and thermolabile variant of methylenetetrahydrofolate reductase among patients with sickle cell disease in Brazil. Am J Hemato1. 1998;59(1):46–50.
   PubMed Web of Science ®Google Scholar
• Kangne HK, Jijina FF, Italia YM, et al. The prevalence of factor V Leiden (G1691A) and methylenetetrahydrofolate reductase C677T mutations in sickle cell disease in Western India. Clin Appl Thromb Hemost. 2015;21(2):186–189.
   PubMed Web of Science ®Google Scholar
• Rahimi Z, Vaisi-Raygani A, Mozafari H, et al. Prevalence of factor V Leiden (G1691A) and prothrombin (G20210A) among Kurdish population from Western Iran. J Thromb Thrombolysis. 2008;25(3):280–283.
   PubMed Web of Science ®Google Scholar
• Zeinali S, Duca F, Zarbakhsh B, et al. Thrombophilic mutations in Iran. Thromb Haemost. 2000;83(2):351–352.
   PubMed Web of Science ®Google Scholar
• Rahimi Z, Vaisi-Raygani A, Nagel RL, Muniz A. Thrombophilic mutations among Southern Iranian patients with sickle cell disease: high prevalence of factor V Leiden. J Thromb Thrombolys. 2008;25(3):288–292.
   PubMed Web of Science ®Google Scholar
• Moreira Neto F, Lourenço DM, Noguti MAE, et al. The clinical impact of MTHFR polymorphism on the vascular complications of sickle cell disease. Brazilian J Med Biol Res. 2006;39(10):1291–1295.
   PubMed Web of Science ®Google Scholar
• Isma’eel H, Shamseddeen AW, Mahfouz R, et al. Screening for inherited thrombophilia might be warranted among Eastern Mediterranean sickle-β0-thalassemia patients. J Thromb Thrombolys. 2006;22(2):121–123.
   PubMed Web of Science ®Google Scholar
• Otrock Z K, Mahfouz RA, Taher AT. Should we screen Eastern Mediterranean sickle β-thalassemia patients for inherited thrombophilia? J Thromb Haemost. 2005;3(3):599–600.
   PubMed Web of Science ®Google Scholar
• Kutlar A, Kutlar F, Turler I, Tural C. The methylenetetrahydrofolate reductase (C677T) mutation as a p otential risk factor for avascular necrosis in sickle cell disease. Hemoglobin. 2001;25(2):213–217.
   PubMed Web of Science ®Google Scholar
• Fawaz NA, Bashawery L, Al-Sheikh I, et al. Factor V-Leiden, prothrombin G20210A, and MTHF R C677T mutations among patients with sickle cell disease in Eastern Saudi Arabia. Am J Hema tol. 2004;76(3):307–309.
   PubMed Web of Science ®Google Scholar
• Cumming AM, Olujohungbe A, Keeney S, et al. The methylenetetrahydrofolate reductase gene C677T polymorphism in patients with homozygous sickle cell disease and stroke. Br J Haematol. 1999;107(3):569–571.
   PubMed Web of Science ®Google Scholar
• Hatzl hofer BL, Bezerra MA, Santos MN, et al. MTHFR polymorphic variant C677T is asociated to vascular complications in sickle cell disease. Genet Test Mol Biomarkers. 2012;16(9):1038–1043.
   PubMed Web of Science ®Google Scholar